Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis

Background: Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are prone to infections.Aims: Provide a pooled estimate of the cumulative incidence for infections that fulfilled the criteria associated with severe infectious adverse events for grade 3 or higher (includi...

Full description

Bibliographic Details
Main Authors: Stephanos Vassilopoulos, Fadi Shehadeh, Markos Kalligeros, Quynh-Lam Tran, Fred Schiffman, Eleftherios Mylonakis
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
chronic lymphocytic leukemia (CLL)
infections
targeted therapies
ibrutinib
idelalisib
monoclonal antibodies
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.989830/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.989830/full

Similar Items